Bremer Trust National Association Takes $1.45 Million Position in Iqvia Holdings Inc (IQV)

Bremer Trust National Association acquired a new stake in shares of Iqvia Holdings Inc (NYSE:IQV) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 14,764 shares of the medical research company’s stock, valued at approximately $1,445,000.

Other large investors also recently made changes to their positions in the company. Nisa Investment Advisors LLC bought a new position in shares of Iqvia during the 4th quarter valued at approximately $920,000. First Citizens Bank & Trust Co. bought a new position in shares of Iqvia during the 4th quarter valued at approximately $1,067,000. Exxonmobil Investment Management Inc. TX bought a new position in shares of Iqvia during the 4th quarter valued at approximately $2,266,000. Franklin Street Advisors Inc. NC bought a new position in shares of Iqvia during the 4th quarter valued at approximately $7,446,000. Finally, DnB Asset Management AS bought a new position in shares of Iqvia during the 4th quarter valued at approximately $8,813,000. Institutional investors own 95.78% of the company’s stock.

In other news, insider Ari Bousbib sold 46,080 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $108.14, for a total transaction of $4,983,091.20. Following the completion of the transaction, the insider now directly owns 1,036,839 shares in the company, valued at approximately $112,123,769.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $101.21, for a total value of $1,012,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,806,558 shares of company stock valued at $898,722,108 over the last quarter. Corporate insiders own 6.40% of the company’s stock.

A number of research analysts recently issued reports on IQV shares. Jefferies Group boosted their price objective on Iqvia from $107.00 to $110.00 and gave the company a “hold” rating in a research note on Monday, October 30th. Zacks Investment Research downgraded Iqvia from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. Mitsubishi UFJ Financial Group started coverage on Iqvia in a research note on Friday, December 15th. They issued a “neutral” rating and a $112.00 price target for the company. Barclays upped their price target on Iqvia from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, October 27th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $125.00 price target (up from $115.00) on shares of Iqvia in a research note on Tuesday, October 31st. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Iqvia has an average rating of “Buy” and a consensus price target of $106.94.

Iqvia Holdings Inc (NYSE IQV) traded up $0.18 during midday trading on Friday, hitting $100.04. The stock had a trading volume of 742,070 shares, compared to its average volume of 1,151,278. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. The company has a market cap of $20,790.00, a P/E ratio of 344.97, a P/E/G ratio of 1.36 and a beta of 0.61. Iqvia Holdings Inc has a 52-week low of $74.80 and a 52-week high of $110.67.

Iqvia (NYSE:IQV) last posted its earnings results on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The firm had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.01 billion. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The company’s quarterly revenue was up 77.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.00 EPS. equities analysts expect that Iqvia Holdings Inc will post 4.62 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://ledgergazette.com/2018/01/12/bremer-trust-national-association-takes-1-45-million-position-in-iqvia-holdings-inc-iqv.html.

About Iqvia

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply